Blood Screening Market by Technology (Nucleic Acid Amplification, (Real-Time PCR), ELISA (Chemiluminescence immunoassay), Rapid Test, Western Blot), Product (Instrument, Reagent & Kits, Software), End User (Blood Bank, Hospital) & Region - Global Forecast to 2026
Instant Answers with GPT - Ask Now!
Ask real questions. Get complete answers !
Generating Response ...Updated on : May 03, 2023
The global blood screening market in terms of revenue was estimated to be worth $2.5 billion in 2021 and is poised to reach $3.8 billion by 2026, growing at a CAGR of 8.4% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The market growth is driven by the rising prevalence of infectious diseases and the increase in need for donated blood.
To know about the assumptions considered for the study, Request for Free Sample Report
Blood Screening Market Dynamics
Driver: Increasing number of blood donations worldwide
There is an increase in need for donated blood because of advancements in healthcare systems and the availability and need for sophisticated surgical procedures, such as cardiovascular and transplant surgery, trauma care, and therapy for cancer and blood diseases. Every year, approximately 235 million major surgeries are performed worldwide, with 63 million being traumatic, over 31 million being cancer-related, and 10 million being related to pregnancy complications. Blood transfusions are usually prescribed in complicated childbirths to prepare for childhood congenital maternal blood disorders, acute anemia, and trauma.
Opportunity: Emerging markets
Emerging markets such as India, the Middle East, and Africa offer promising opportunities for players in the blood screening industry due to their increasing disposable incomes and improving healthcare infrastructure. For instance, according to Statista (August 2021), in 2017, India’s healthcare sector was worth about USD 160 billion, and it was estimated to reach USD 372 billion by 2022 due to rising income levels, increasing awareness about health, and the increasing incidence of lifestyle diseases year on year. Because NAT has a low penetration rate in India, ELISA is currently the most widely used technology. Unlike the US, Canada, most of Europe, Japan, Korea, Singapore, Sri Lanka, the UAE, South Africa, Thailand, and China, NAT is still not mandatory in India. Almost 100 blood banks, including AIIMS, PGI Chandigarh, CMC Vellore, Medanta-The Medicity, and Narayana Hrudayalaya, are using NAT in ID-NAT format, whereas around 40 blood banks are using the pooling technique. Thus, an initiative is taken by the Indian government to train doctors, hospitals, and blood banks on using NAT.
Restraint: Alternative technologies
Digital immunoassays are a one-step solution for single-molecule detection without requiring washing steps based on ELISA using an array of femtoliter-sized wells. In this assay, a biomarker molecule is conjugated with an antibody-coated magnetic microparticle seeded in a well, amplified via an enzymatic reaction, and detected with fluorescence. These tests have seen significant interest due to the urgent and ever-increasing demand for serological COVID-19 antibody tests that are inexpensive, rapid, simple, highly sensitive, quantitative, and minimally invasive. Therefore, a single-step, wash-free immunoassay for rapid and highly sensitive quantitative analysis of human serological IgG against SARS-CoV-2 has been developed, which requires only a single droplet of serum.
Challenge: High cost of blood screening technologies
Given the rise in donations of blood, awareness about blood safety, and the expenditure on healthcare across the globe, newer technologies are extensively used in high-income countries and will be successfully adopted in middle- and lower-income countries in the next decade. However, many developing countries, such as India and China, currently rely on ELISA. In the current timeframe, the growth of the blood screening market for NAT is majorly inhibited. The advanced tests with high costs have driven the greater use of first-generation ELISA, which is older and less efficient. This test is used in many parts of the world, despite its limitations. For instance, the global donor-supported cost of USD 9.98 per GeneXpert MTB/RIF cartridge is seen as unaffordable for many low- and middle-income countries' (LMIC) TB programs.
The global market is highly consolidated. The top players—Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), BioMérieux (France), and Bio-Rad Laboratories, Inc. (US)—in the blood screening market accounted for a combined majority market share in 2020. There is a high degree of competition among the market players. Only major companies can afford high capital investments as well as the high cost of R&D and manufacturing. This will prevent new entrants from entering this market.
Reagents & kits segment accounted for the largest share of the blood screening market, by product & service.
The market is segmented into reagents & kits, instruments, and software & services. Reagents and kits accounted for the largest share of this market, mainly due to an increase in blood transfusion procedures, due to which there is more consumption and repeated use of reagents and kits in blood screening procedures.
Nucleic acid test segment accounted for the largest share in the blood screening market, by technology.
The market is segmented into nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). The nucleic acid test (NAT) segment accounted for the largest share of the global market. Factors such as the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies and rising number of blood donations.
Blood banks and hospitals segment accounted for the largest share in the blood screening market, by end user.
The market is segmented into blood banks and hospitals. The blood banks segment accounted for the largest share of the global market. The growing number of organ transplant surgeries is driving the growth of this segment.
North America is the largest region for blood screening market.
The market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. North America accounted for the largest share of the global market. The growth of the North American market can be attributed to the increasing healthcare spending, the increasing prevalence of chronic disorders, and the highly developed healthcare systems in the US and Canada.
To know about the assumptions considered for the study, download the pdf brochure
Prominent players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US) among others.
Blood Screening Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$2.5 billion |
|
Projected Revenue by 2026 |
$3.8 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 8.4% |
|
Market Driver |
Rising number of blood donations |
|
Market Opportunity |
Technological advancements |
This study categorizes the global Blood Screening Market to forecast revenue and analyze trends in each of the following submarkets:
By Product & Service
-
Reagents & Kits
-
NAT Reagents & Kits
- Enzymes & Polymerases
- Standards & Controls
- Probes & Primers
- Buffers, Nucleotides, and Solutions
- Labeling & Detection Reagents
-
ELISA Reagents & Kits
- Immunosorbents
- Controls
- Conjugates
- Substrates
- Sample Diluents & Wash Solutions
- Other Reagents & Kits
-
NAT Reagents & Kits
-
Instruments
- Rental Purchase
- Outright Purchase
- Software & Services
By Technology
-
Nucleic Acid Test
- Transcription-mediated Amplification
- Real-time PCR
-
ELISA
- Chemiluminescent Immunoassays
- Fluorescent Immunoassays
- Colorimetric Immunoassays
- Rapid Tests
- Western Blot Assays
- Next-generation Sequencing
By End User
- Blood Banks
- Hospitals
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
-
Latin America
- Australia
- Rest of Latin America
- Middle East & Africa
Recent Developments
- In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.
- In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.
- In February 2020, BD (US) acquired NAT Diagnostics (US), this acquisition strengthened an early-stage company developing a molecular diagnostic platform for POC testing.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global blood screening market?
The global blood screening market boasts a total revenue value of $3.8 billion by 2026.
What is the estimated growth rate (CAGR) of the global blood screening market?
The global market for blood screening has an estimated compound annual growth rate (CAGR) of 8.4% and a revenue size in the region of $2.5 billion in 2021.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 22)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
1.2.2 MARKETS COVERED
FIGURE 1 BLOOD SCREENING MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 27)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 2 BLOOD SCREENING MARKET: RESEARCH DESIGN
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (GLOBAL MARKET)
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 7 GLOBAL MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 ASSUMPTIONS FOR THE STUDY
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
2.8.1 RISK ASSESSMENT: GLOBAL MARKET
2.9 GROWTH RATE ASSUMPTIONS
2.10 COVID-19 HEALTH ASSESSMENT
2.11 COVID-19 ECONOMIC ASSESSMENT
2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
2.13 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE GLOBAL MARKET
3 EXECUTIVE SUMMARY (Page No. - 44)
FIGURE 11 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
FIGURE 12 GLOBAL MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
FIGURE 13 GLOBAL MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 14 GLOBAL MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 47)
4.1 BLOOD SCREENING MARKET OVERVIEW
FIGURE 15 GROWING NUMBER OF BLOOD DONATIONS AND INCREASING PREVALENCE OF INFECTIOUS DISEASES DRIVE MARKET GROWTH
4.2 GLOBAL MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
FIGURE 16 REAGENTS & KITS SEGMENT WILL CONTINUE TO DOMINATE THE MARKET IN 2026
4.3 GLOBAL MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
FIGURE 17 NUCLEIC ACID TEST SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
4.4 GLOBAL MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 18 BLOOD BANKS SEGMENT TO CONTINUE TO DOMINATE THE MARKET IN 2026
4.5 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE GLOBAL MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 50)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 BLOOD SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising number of blood donations
TABLE 1 GLOBAL CANCER PREVALENCE, 2018 VS. 2025
5.2.1.2 Rising prevalence of infectious diseases and emergence of newer pathogens
5.2.2 RESTRAINTS
5.2.2.1 Alternative technologies
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements
5.2.3.2 Emerging economies offer lucrative opportunities
5.2.4 CHALLENGES
5.2.4.1 High cost of blood screening technologies
5.2.4.2 Usage of low-sensitivity screening
5.3 IMPACT OF COVID-19 ON THE GLOBAL MARKET
5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS
5.4.1 GLOBAL MARKET
FIGURE 21 PESSIMISTIC SCENARIO
FIGURE 22 OPTIMISTIC SCENARIO
FIGURE 23 REALISTIC SCENARIO
5.5 PRICING ANALYSIS
TABLE 2 PRICE OF BLOOD SCREENING PRODUCTS (2021)
5.6 PATENT ANALYSIS
5.6.1 PATENT ANALYSIS OF NAT
5.6.2 PATENT ANALYSIS OF ELISA
5.7 TRADE ANALYSIS
5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC REAGENTS
TABLE 3 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 4 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)
5.8 VALUE CHAIN ANALYSIS
FIGURE 24 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASE
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 25 GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
5.10 ECOSYSTEM ANALYSIS OF THE GLOBAL MARKET
FIGURE 26 GLOBAL MARKET: ECOSYSTEM ANALYSIS
5.10.1 ROLE IN ECOSYSTEM
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF BUYERS
5.11.4 BARGAINING POWER OF SUPPLIERS
5.11.5 DEGREE OF COMPETITION
5.12 REGULATORY LANDSCAPE
5.12.1 NORTH AMERICA
5.12.1.1 US
5.12.1.2 CANADA
5.12.2 EUROPE
5.12.3 ASIA PACIFIC
5.12.3.1 JAPAN
5.12.3.2 INDIA
5.12.4 LATIN AMERICA
5.12.4.1 BRAZIL
5.12.5 MIDDLE EAST
5.13 CASE STUDY ANALYSIS
5.13.1 CASE STUDY 1
5.13.2 CASE STUDY 2
5.14 TECHNOLOGY ANALYSIS
5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS
5.15.1 REVENUE SOURCES ARE SHIFTING TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO THE COVID-19 PANDEMIC
FIGURE 27 REVENUE SHIFT FOR THE BLOOD SCREENING MARKET
6 BLOOD SCREENING MARKET, BY PRODUCT & SERVICE (Page No. - 69)
6.1 INTRODUCTION
TABLE 6 GLOBAL MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
6.2 REAGENTS & KITS
TABLE 7 KEY PRODUCTS IN THE REAGENTS & KITS MARKET
TABLE 8 BLOOD SCREENING REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 9 BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2.1 NAT REAGENTS & KITS
6.2.1.1 High sensitivity and rising use of NAT are boosting the demand for reagents & kits
6.2.1.2 Enzymes & polymerases
6.2.1.3 Standards & controls
6.2.1.4 Probes & primers
6.2.1.5 Buffers, nucleotides, and solutions
6.2.1.6 Labeling & detection reagents
6.3 PRIMARY NOTES
6.3.1 KEY INDUSTRY INSIGHTS
TABLE 10 KEY PRODUCTS IN THE NAT REAGENTS & KITS MARKET
TABLE 11 NAT REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 NAT REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.3.2 ELISA REAGENTS & KITS
6.3.2.1 Ease of use and cost-effectiveness of ELISA reagents & kits will drive the market growth
6.3.2.2 Immunosorbents
6.3.2.3 Controls
6.3.2.4 Conjugates
6.3.2.5 Substrates
6.3.2.6 Sample diluents & wash solutions
TABLE 13 KEY PRODUCTS IN THE ELISA REAGENTS & KITS MARKET
TABLE 14 ELISA REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 15 ELISA REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.3.3 OTHER REAGENTS & KITS
TABLE 16 KEY PRODUCTS IN THE OTHER REAGENTS & KITS MARKET
TABLE 17 OTHER BLOOD SCREENING REAGENTS & KITS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.4 INSTRUMENTS
TABLE 18 KEY PRODUCTS IN THE BLOOD SCREENING INSTRUMENTS MARKET
TABLE 19 BLOOD SCREENING INSTRUMENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 20 BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
6.4.1 RENTAL PURCHASE
6.4.1.1 Convenience and cost-effectiveness of renting instruments has resulted in a greater end-user preference
TABLE 21 RENTAL PURCHASE MARKET FOR BLOOD SCREENING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.4.2 OUTRIGHT PURCHASE
6.4.2.1 Availability of government support will increase the outright purchase of instruments
TABLE 22 OUTRIGHT PURCHASE MARKET FOR BLOOD SCREENING INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)
6.5 SOFTWARE & SERVICES
6.5.1 GROWING PURCHASE OF INSTRUMENTS WILL DRIVE DEMAND FOR SOFTWARE & SERVICES
TABLE 23 KEY PRODUCTS IN THE SOFTWARE & SERVICES MARKET
TABLE 24 BLOOD SCREENING SOFTWARE & SERVICES, BY REGION, 2019–2026 (USD MILLION)
7 BLOOD SCREENING MARKET, BY TECHNOLOGY (Page No. - 83)
7.1 INTRODUCTION
TABLE 25 GLOBAL MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.2 NUCLEIC ACID TEST
TABLE 26 KEY PRODUCTS IN THE NAT MARKET
TABLE 27 GLOBAL MARKET FOR NAT, BY REGION, 2019–2026 (USD MILLION)
TABLE 28 GLOBAL MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
7.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION
7.2.1.1 High sensitivity of these assays to support the market growth
TABLE 29 TMA MARKET, BY REGION, 2019–2026 (USD MILLION)
7.2.2 REAL-TIME POLYMERASE CHAIN REACTION
7.2.2.1 Real-time PCR provides more accurate and effective results as compared to conventional PCR
TABLE 30 RT-PCR MARKET, BY REGION, 2019–2026 (USD MILLION)
7.3 ENZYME-LINKED IMMUNOSORBENT ASSAY
TABLE 31 KEY PRODUCTS IN THE ELISA MARKET
TABLE 32 GLOBAL MARKET FOR ELISA, BY REGION, 2019–2026 (USD MILLION)
TABLE 33 GLOBAL MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
7.3.1 CHEMILUMINESCENT IMMUNOASSAYS
7.3.1.1 CLIA is ultra-sensitive, automated, and a good alternative to conventional technologies
TABLE 34 CLIA MARKET, BY REGION, 2019–2026 (USD MILLION)
7.3.2 FLUORESCENT IMMUNOASSAYS
7.3.2.1 Rising demand for safer and stable reagents and the development of novel markers to support the growth of the FIA market
TABLE 35 FIA MARKET, BY REGION, 2019–2026 (USD MILLION)
7.3.3 COLORIMETRIC IMMUNOASSAYS
7.3.3.1 CI offers low sensitivity as it uses vulnerable/limited signal amplification strategies
TABLE 36 CIA MARKET, BY REGION, 2019–2026 (USD MILLION)
7.4 RAPID TESTS
7.4.1 RISING AWARENESS ABOUT RAPID TESTS IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH
TABLE 37 KEY PRODUCTS IN THE RAPID TESTS TECHNOLOGY MARKET
TABLE 38 GLOBAL MARKET FOR RAPID TESTS, BY REGION, 2019–2026 (USD MILLION)
7.5 WESTERN BLOT ASSAYS
7.5.1 GROWING PREVALENCE OF TTIS IN DEVELOPING COUNTRIES HAS RESULTED IN THE INCREASED DEMAND FOR WESTERN BLOT ASSAYS
TABLE 39 KEY PRODUCTS IN THE WESTERN BLOT ASSAYS MARKET
TABLE 40 GLOBAL MARKET FOR WESTERN BLOT ASSAYS, BY REGION, 2019–2026 (USD MILLION)
7.6 NEXT-GENERATION SEQUENCING
7.6.1 NGS IS AN EMERGING TECHNOLOGY IN THE GLOBAL MARKET
TABLE 41 GLOBAL MARKET FOR NGS, BY REGION, 2019–2026 (USD MILLION)
8 BLOOD SCREENING MARKET, BY END USER (Page No. - 98)
8.1 INTRODUCTION
TABLE 42 GLOBAL MARKET, BY END USER, 2019–2026 (USD MILLION)
8.2 BLOOD BANKS
8.2.1 RISING DEMAND FOR BLOOD ATTRIBUTED TO INCREASING BLOOD DISORDER INCIDENCE
8.2.2 KEY INDUSTRY INSIGHTS
TABLE 43 GLOBAL MARKET FOR BLOOD BANKS, BY REGION, 2019–2026 (USD MILLION)
8.3 HOSPITALS
8.3.1 INCREASING SURGICAL PROCEDURES WILL DRIVE THE GROWTH OF THE HOSPITALS SEGMENT
TABLE 44 GLOBAL MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
9 BLOOD SCREENING MARKET, BY REGION (Page No. - 102)
9.1 INTRODUCTION
TABLE 45 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: BLOOD SCREENING MARKET SNAPSHOT
TABLE 46 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 49 NORTH AMERICA: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 50 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 51 NORTH AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.1 US
9.2.1.1 The US dominated the North American blood screening market in 2020
TABLE 54 INCIDENCE OF VARIOUS CANCERS IN THE US, 2018 VS. 2025
TABLE 55 US: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 56 US: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 57 US: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 58 US: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 59 US: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 60 US: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 61 US: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Growing volume of surgical procedures performed and high burden of cancer to support market growth
TABLE 62 CANADA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 63 CANADA: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 64 CANADA: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 65 CANADA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 66 CANADA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 CANADA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 68 CANADA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3 EUROPE
TABLE 69 EUROPE: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 70 EUROPE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 71 EUROPE: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 EUROPE: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 73 EUROPE: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 74 EUROPE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 EUROPE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 76 EUROPE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Higher healthcare spending and increase in cancer prevalence drives market growth
TABLE 77 GERMANY: KEY MACROINDICATORS
TABLE 78 GERMANY: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 79 GERMANY: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 GERMANY: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 81 GERMANY: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 82 GERMANY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 GERMANY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 84 GERMANY: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.2 FRANCE
9.3.2.1 Increasing prevalence of HIV to support the market growth
TABLE 85 FRANCE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 86 FRANCE: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 FRANCE: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 88 FRANCE: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 89 FRANCE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 90 FRANCE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 91 FRANCE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.3 UK
9.3.3.1 Government support to prevent transmission of HIV and other infections will drive market growth
TABLE 92 UK: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 93 UK: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 UK: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 95 UK: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 96 UK: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 UK: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 98 UK: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Italy is witnessing an increase in the number of blood donors
TABLE 99 ITALY: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 100 ITALY: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 101 ITALY: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 102 ITALY: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 103 ITALY: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 ITALY: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 105 ITALY: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Increasing adoption of NAT technology will support market growth
TABLE 106 SPAIN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 107 SPAIN: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 SPAIN: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 109 SPAIN: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 110 SPAIN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 111 SPAIN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 112 SPAIN: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 113 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP)
TABLE 114 ROE: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 115 ROE: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 116 ROE: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 117 ROE: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 118 ROE: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 119 ROE: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 120 ROE: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: BLOOD SCREENING MARKET SNAPSHOT
TABLE 121 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 122 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 123 ASIA PACIFIC: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 124 ASIA PACIFIC: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 125 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 126 ASIA PACIFIC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 127 ASIA PACIFIC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 128 ASIA PACIFIC: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.1 CHINA
9.4.1.1 China has a high prevalence of infectious diseases
TABLE 129 CHINA: KEY MACROINDICATORS
TABLE 130 CHINA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 131 CHINA: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 132 CHINA: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 133 CHINA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 134 CHINA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 135 CHINA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 136 CHINA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Rising geriatric population and prevalence of cancer support market growth
TABLE 137 JAPAN: KEY MACROINDICATORS
TABLE 138 JAPAN: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 139 JAPAN: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 140 JAPAN: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 141 JAPAN: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 142 JAPAN: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 143 JAPAN: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 144 JAPAN: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Increasing number of road accidents and rise in prevalence of thalassemia will support the market growth
TABLE 145 INDIA: KEY MACROINDICATORS
TABLE 146 INDIA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 147 INDIA: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 148 INDIA: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 149 INDIA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 150 INDIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 151 INDIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 152 INDIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.4 AUSTRALIA
9.4.4.1 Increased demand for blood donations will propel market growth
TABLE 153 AUSTRALIA: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 154 AUSTRALIA: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 155 AUSTRALIA: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 156 AUSTRALIA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 157 AUSTRALIA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 158 AUSTRALIA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 159 AUSTRALIA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 160 ROAPAC: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 161 ROAPAC: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 162 ROAPAC: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 163 ROAPAC: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 164 ROAPAC: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 165 ROAPAC: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 166 ROAPAC: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5 LATIN AMERICA
TABLE 167 LATIN AMERICA: BLOOD SCREENING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 168 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 169 LATIN AMERICA: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 170 LATIN AMERICA: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 171 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 172 LATIN AMERICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 173 LATIN AMERICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 174 LATIN AMERICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.1 BRAZIL
9.5.1.1 Increased prevalence of cancer will support the market growth
TABLE 175 INCIDENCE OF VARIOUS CANCERS IN BRAZIL, 2020 VS. 2025
TABLE 176 BRAZIL: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 177 BRAZIL: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 178 BRAZIL: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 179 BRAZIL: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 180 BRAZIL: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 181 BRAZIL: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 182 BRAZIL: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.5.2 REST OF LATIN AMERICA
TABLE 183 ROLATAM: BLOOD SCREENING MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 184 ROLATAM: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 ROLATAM: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 186 ROLATAM: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 187 ROLATAM: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 188 ROLATAM: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 189 ROLATAM: MARKET, BY END USER, 2019–2026 (USD MILLION)
9.6 MIDDLE EAST & AFRICA
9.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
TABLE 190 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
TABLE 191 MIDDLE EAST & AFRICA: MARKET FOR NAT, BY TYPE, 2019–2026 (USD MILLION)
TABLE 192 MIDDLE EAST & AFRICA: MARKET FOR ELISA, BY PLATFORM, 2019–2026 (USD MILLION)
TABLE 193 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
TABLE 194 MIDDLE EAST & AFRICA: BLOOD SCREENING REAGENTS & KITS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 MIDDLE EAST & AFRICA: BLOOD SCREENING INSTRUMENTS MARKET, BY PURCHASE TYPE, 2019–2026 (USD MILLION)
TABLE 196 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 167)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE BLOOD SCREENING MARKET
TABLE 197 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BLOOD SCREENING MANUFACTURING COMPANIES
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 30 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE GLOBAL MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 31 GLOBAL MARKET SHARE, BY KEY PLAYER (2020)
TABLE 198 GLOBAL MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT
10.5.1 LIST OF EVALUATED VENDORS
10.5.2 STARS
10.5.3 EMERGING LEADERS
10.5.4 PERVASIVE PLAYERS
10.5.5 PARTICIPANTS
FIGURE 32 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
10.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
10.6.1 PROGRESSIVE COMPANIES
10.6.2 STARTING BLOCKS
10.6.3 RESPONSIVE COMPANIES
10.6.4 DYNAMIC COMPANIES
FIGURE 33 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
10.7 COMPETITIVE BENCHMARKING
10.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN THE BLOOD SCREENING MARKET
TABLE 199 PRODUCT FOOTPRINT OF COMPANIES
TABLE 200 REGIONAL FOOTPRINT OF COMPANIES
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
TABLE 201 KEY PRODUCT LAUNCHES
10.8.2 DEALS
TABLE 202 KEY DEALS
11 COMPANY PROFILES (Page No. - 177)
(Business Overview, Products, Key Insights, Recent Developments, MnM View)*
11.1 KEY PLAYERS
11.1.1 F. HOFFMANN-LA ROCHE
TABLE 203 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 35 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2020)
11.1.2 GRIFOLS
TABLE 204 GRIFOLS: BUSINESS OVERVIEW
FIGURE 36 GRIFOLS: COMPANY SNAPSHOT (2020)
11.1.3 ABBOTT LABORATORIES
TABLE 205 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 37 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
11.1.4 BIOMÉRIEUX
TABLE 206 BIOMÉRIEUX: BUSINESS OVERVIEW
FIGURE 38 BIOMÉRIEUX: COMPANY SNAPSHOT (2020)
11.1.5 BIO-RAD LABORATORIES
TABLE 207 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
FIGURE 39 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2020)
11.1.6 BECTON, DICKINSON AND COMPANY
TABLE 208 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 40 BD: COMPANY SNAPSHOT (2020)
11.1.7 DANAHER CORPORATION
TABLE 209 DANAHER CORPORATION.: BUSINESS OVERVIEW
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
11.1.8 DIASORIN
TABLE 210 DIASORIN: BUSINESS OVERVIEW
FIGURE 42 DIASORIN: COMPANY SNAPSHOT (2020)
11.1.9 SIEMENS HEALTHINEERS
TABLE 211 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
FIGURE 43 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)
11.1.10 THERMO FISHER SCIENTIFIC, INC.
TABLE 212 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 44 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
(Business Overview, Products, Key Insights, Recent Developments, MnM View)*
11.2 OTHER PLAYERS
11.2.1 ORTHO CLINICAL DIAGNOSTICS, INC.
11.2.2 GE HEALTHCARE
11.2.3 MERCK KGAA
11.2.4 PERKINELMER
11.2.5 BIO-TECHNE CORPORATION
11.2.6 GFE
11.2.7 TRINITY BIOTECH
11.2.8 J. MITRA & CO. PVT. LTD.
11.2.9 MINDRAY
11.2.10 MACCURA BIOTECHNOLOGY CO., LTD.
11.2.11 IMMUCOR, INC.
11.2.12 CELLABS
11.2.13 ABNOVA CORPORATION
11.2.14 ENZO BIOCHEM, INC.
11.2.15 CEPHEID
12 APPENDIX (Page No. - 228)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the blood screening market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate segments and subsegments' market size.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the blood screening market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the blood screening market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, segment, and forecast the global blood screening market by product & service, technology, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall blood screening market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches, agreements, partnerships, and acquisitions in the blood screening market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Country Information
- Blood screening market size and growth rate estimates for countries in the Rest of Europe, the Rest of Asia Pacific, Latin America, and Middle East & Africa
Company profiles
- Additional five company profiles of players operating in the blood screening market.
Growth opportunities and latent adjacency in Blood Screening Market
1) We would like to mention that total market size of NAT in Germany (60.8 million in 2015), Europe and US and even others remains the same. However, contribution of RTPCR and TMA will differ. We have done that correction in the report and are sharing the updated report with you in a few minutes. However, we will conduct some further primary interviews to re-validate this data. After re-validation, if any changes/discrepancies found in the further research, we share another version if needed. 2) (NAT) includes overall molecular diagnostics products (Reagents, kits, Instruments (Analysers), Software and Services) used for the blood screening test by all type of end users such as Hospitals and Blood Banks. This number (USD 66.6 million in 2016) is largely sum of TMA and PCR based NAT testing used for blood screening. These tests are being used by blood banks and hospitals. According to WHO report (published in 2016), in 2013, there were around 70 blood centres in Germany. 3) We have identified Ortho Clinical Diagnostics as a leading player. But it will not come in top 5 players. On the basis of our analysis and product offerings we have listed it in top 10 companies (at 6th position).
What are the challenges faced by the key players of the Blood Screening Market?
Which of the segments of Blood Screening Market is expected to hold the major share?
How the technological innovations are boosting the global growth of Blood Screening Market?